Entera Bio

Entera Bio CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Entera Bio (ENTX) as of Oct 17, 2026 is -1.45 %. In the previous year, CapEx to Operating Cash Flow Ratio was -0.04 % — a change of 3,199.53% (lower).

CapEx/OCF

-1.45 %

YoY

3,199.53%

Last updated:

CapEx to Operating Cash Flow Ratio of Entera Bio is 2025 -1.45 % . CapEx to Operating Cash Flow Ratio of Entera Bio was 2024 -0.04 % . It decreases by 3,199.53% lower compared to the previous year.

The Entera Bio CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-0.69 USD
Jan 1, 2019
-0.45 USD
Jan 1, 2020
-0.50 USD
Jan 1, 2021
-0.19 USD
Jan 1, 2022
-0.38 USD
Jan 1, 2023
-0.23 USD
Jan 1, 2024
-0.04 USD
Jan 1, 2025
-1.45 USD
The Entera Bio CapEx/OCF history
YEARCapEx/OCFYoY
-1.45 %+3,199.53%
-0.04 %-81.08%
-0.23 %-38.15%
-0.38 %+100.46%
-0.19 %-62.64%
-0.50 %+11.94%
-0.45 %-35.39%
-0.69 %-38.40%
-1.13 %-13.65%
-1.30 %-15.54%
-1.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

CapEx to Operating Cash Flow Ratio of Entera Bio is -1.45 % in 2025.

CapEx to Operating Cash Flow Ratio of Entera Bio changed from -0.04 % to -1.45 %, representing a 3,199.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Entera Bio since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Entera Bio

All Key Metrics — Entera Bio